# EDGAR Filing Document

**Accession Number:** 0001450416
**File Stem:** 0001062993-23-002545
**Filing Date:** 2023-2
**Character Count:** 47331
**Document Hash:** ab3a121841d8c8547807c6f08ef1bce8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-002545.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001062993-23-002545

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**EFFECTIVENESS DATE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LexaGene Holdings Inc.
- **CENTRAL INDEX KEY:** 0001450416
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269660
- **FILM NUMBER:** 23605557

**BUSINESS ADDRESS:**
- **STREET 1:** 500 CUMMINGS CTR., SUITE 4550
- **CITY:** BEVERLY
- **STATE:** MA
- **ZIP:** 01915
- **BUSINESS PHONE:** 800-215-1824

**MAIL ADDRESS:**
- **STREET 1:** 500 CUMMINGS CTR., SUITE 4550
- **CITY:** BEVERLY
- **STATE:** MA
- **ZIP:** 01915

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STONESHIELD CAPITAL CORP.
- **DATE OF NAME CHANGE:** 20100729

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STONESHIELD CAPITAL CORP
- **DATE OF NAME CHANGE:** 20081119

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

![](forms8x002.jpg)

<u>**LEXAGENE HOLDINGS INC.**</u>

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| &nbsp;&nbsp;<u>**British Columbia**</u><br>(State or other jurisdiction of<br>incorporation or organization) | &nbsp;&nbsp;<u>**None**</u><br>(I.R.S. Employer Identification No.) |

---

**500 Cummings Center, Suite 4550,**

<u>**Beverly, Massachusetts 01915**</u>

(Address of principal executive offices)

**‎LEXAGENE HOLDINGS, INC. OMNIBUS INCENTIVE PLAN, AS AMENDED**

(Full title of the plan)

**LexaGene, Inc.**

**500 Cummings Center, Suite 4550, Beverly, Massachusetts 01915**

(Name and address of agent of service)

**1-800-215-1824**

(Telephone number, including are code, of agent of service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp; Large accelerated filer | &nbsp;&nbsp;[ ] | &nbsp;&nbsp; Accelerated filer | &nbsp;&nbsp;[ ] |
| &nbsp;&nbsp; Non-accelerated filer | &nbsp;&nbsp; [ X ] | &nbsp;&nbsp; Smaller reporting company | &nbsp;&nbsp; [ X ] |
|  |  | &nbsp;&nbsp; Emerging growth company | &nbsp;&nbsp; [ X ] |

---

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financing accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [ ]

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (the "**Registration Statement**") is being filed to register (a) an aggregate of 8,421,344 common shares of Lexagene Holdings Inc. (the "**Company**" or the "**Registrant**") issuable pursuant to awards granted under the Company's Omnibus Incentive Plan, as amended (the "**OIP**"), and pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "**Securities Act**"), any additional common shares that become issuable under the OIP by reason of any stock dividend, stock split, or other similar transaction.

**Part I - Information Required in the Section 10(a) Prospectus**

Item 1. <u>Plan Information</u>. \*

Item 2. <u>Registrant Information and Employee Plan Annual Information</u>. \*

**\*** The documents containing the information specified in "Item 1. Plan Information" and "Item 2. Registrant Information and Employee Plan Annual Information" of Form S-8 will be sent or given to participants, as specified by Rule 428(b)(1) under the Securities Act. Such documents are not required to be, and are not, filed with the United States Securities and Exchange Commission (the "**Commission**") either as part of this registration statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this registration statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**Part II - Information Required in the Registration Statement**

Item 3. <u>Incorporation of the Documents by Reference</u>.

The following documents filed by the Registrant with the Commission are incorporated herein by reference:

[(a)](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_1012g.htm) [The Registrant's registration statement on Form 10 (the "**Form 10 Registration Statement**") under the United States Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), filed with the SEC on June 28, 2022;](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_1012g.htm)

[(b)](http://www.sec.gov/Archives/edgar/data/1450416/000110465922087866/tm2210382d2_1012ga.htm) [Amendment No. 1 to the Form 10 Registration Statement (the "**Amended Form 10 Registration Statement**", filed with the SEC on August 9, 2022;](http://www.sec.gov/Archives/edgar/data/1450416/000110465922087866/tm2210382d2_1012ga.htm)

[(c)](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465922109746/lxxgf-20220831x10q.htm) [The Registrant's quarterly report on Form 10-Q for the quarterly period ended August 31, 2022, filed with the SEC pursuant to section 13(a) of the Exchange Act on October 18, 2022;](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465922109746/lxxgf-20220831x10q.htm)

[(d)](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465922111426/tm2228906d1_8k.htm) [The Registrant's Current Report on Form 8-K filed with the SEC pursuant to section 13(a) of the Exchange Act on October 26, 2022;](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465922111426/tm2228906d1_8k.htm)

------

[(e)](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465922113653/tm2229433d1_8k.htm) [The Registrant's Current Report on Form 8-K filed with the SEC pursuant to section 13(a) of the Exchange Act on November 2, 2022 (only with respect to information filed under item 2.03);](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465922113653/tm2229433d1_8k.htm)

[(f)](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) [The Registrant's definitive proxy statement on Schedule 14A (the "**Proxy Statement**") that we filed with the SEC pursuant to section 14(a) of the Exchange Act on December 30, 2022;](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm)

[(g)](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465923004303/lxxgf-20221130x10q.htm) [The Registrant's quarterly report on Form 10-Q for the quarterly period ended November 30, 2022, filed with the SEC pursuant to section 13(a) of the Exchange Act on January 17, 2023;](http://www.sec.gov/ix?doc=/Archives/edgar/data/1450416/000110465923004303/lxxgf-20221130x10q.htm)

[(h)](http://www.sec.gov/ix?doc=/Archives/edgar/data/0001450416/000110465923014355/tm235853d2_8k.htm) [The Registrant's Current Report on Form 8-K filed with the SEC pursuant to section 13(a) of the Exchange Act on February 8, 2023;](http://www.sec.gov/ix?doc=/Archives/edgar/data/0001450416/000110465923014355/tm235853d2_8k.htm)

[(i)](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_1012g.htm) [The description of the Registrant's Common Shares contained in Item 11, *Description of the Registrant's Securities to be Registered*, of the Form 10 Registration Statement, incorporated by reference herein pursuant to (a) above, including any amendment or report filed for the purposes of updating such description.](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_1012g.htm)

All reports or other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the United States Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof commencing on the respective dates on which such documents are filed. Notwithstanding the foregoing, unless specifically stated to the contrary in such filing, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise be included in or deemed to be a part of, this Registration Statement.

Any statement contained in a document incorporated by reference into this Registration Statement shall be deemed to be modified or superseded for purposes hereof to the extent that a statement contained herein (or in any other subsequently filed document which also is or is deemed incorporated herein) modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part hereof, except as so modified or superseded.

Item 4. <u>Description of Securities</u>.

Not applicable.

Item 5. <u>Interests of Named Experts and Counsel</u>.

No expert or counsel named in this Registration Statement as having prepared or certified any part of this Registration Statement or having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of such securities was employed on a contingency basis, or had, or is to receive, in connection with the offering, a substantial interest, direct or indirect, in our Company, nor was any such person connected with us as a promoter, managing or principal underwriter, voting trustee, director, officer, or employee.

------

Item 6. <u>Indemnification of Directors and Officers</u>.

The Registrant is subject to the provisions of Part 5, Division 5 of the Business Corporations Act (British Columbia) (the "**BCBCA**"). Under Section 160 of the BCBCA, the Registrant may, subject to Section 163 of the BCBCA:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) indemnify an individual who:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) is or was a director of officer of the Registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) is or was a director or officer of another corporation at a time when such corporation is or was an affiliate of the Registrant; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) at the Registrant's request, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity, including, subject to certain limited exceptions, the heirs and personal or other legal representatives of that individual (collectively, an "eligible party"), against all eligible penalties, defined below, to which the eligible party is or may be liable; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) after final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, where:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) "eligible penalty" means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) "eligible proceeding" means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Registrant or an associated corporation (A) is or may be joined as a party, or (B) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) "expenses" includes costs, charges and expenses, including legal and other fees, but does not include judgments, penalties, fines or amounts paid in settlement of a proceeding, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) "proceeding" includes any legal proceeding or investigative action, whether current, threatened, pending or completed.

Under Section 161 of the BCBCA, and subject to Section 163 of the BCBCA, the Registrant must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding if the eligible party (a) has not been reimbursed for those expenses and (b) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding.

------

Under Section 162 of the BCBCA, and subject to Section 163 of the BCBCA, the Registrant may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of the proceeding, provided that the Registrant must not make such payments unless it first receives from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited under Section 163 of the BCBCA, the eligible party will repay the amounts advanced.

Under Section 163 of the BCBCA, the Registrant must not indemnify an eligible party against eligible penalties to which the eligible party is or may be liable or pay the expenses of an eligible party in respect of that proceeding under Sections 160(b), 161 or 162 of the BCBCA, as the case may be, if any of the following circumstances apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if the indemnity or payment is made under an agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, the Registrant was prohibited from giving the indemnity or paying the expenses by the Registrant's memorandum or Articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, the Registrant is prohibited from giving the indemnity or paying the expenses by the Registrant's memorandum or Articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of the Registrant or the associated corporation, as the case may be; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party's conduct in respect of which the proceeding was brought was lawful.

If an eligible proceeding is brought against an eligible party by or on behalf of the Registrant or by or on behalf of an associated corporation, the Registrant must not either indemnify the eligible party under Section 160(a) of the BCBCA against eligible penalties to which the eligible party is or may be liable, or pay the expenses of the eligible party under Sections 160(b), 161 or 162 of the BCBCA, as the case may be, in respect of the proceeding.

Under Section 164 of the BCBCA, and despite any other provision of Part 5, Division 5 of the BCBCA and whether or not payment of expenses or indemnification has been sought, authorized or declined under Part 5, Division 5 of the BCBCA, on application of the Registrant or an eligible party, the court may do one or more of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) order the Registrant to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) order the Registrant to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) order the enforcement of, or any payment under, an agreement of indemnification entered into by us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) order the Registrant to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under Section 164 of the BCBCA; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) make any other order the court considers appropriate.

Section 165 of the BCBCA provides that the Registrant may purchase and maintain insurance for the benefit of an eligible party or the heirs and personal or other legal representatives of the eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Registrant or an associated corporation.

Under Article 20.2 of the Registrant's Articles, and subject to the BCBCA, the Registrant must indemnify an eligible party and his or her heirs and legal personal representatives against all eligible penalties to which such person is or may be liable, and it must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each eligible party is deemed to have contracted with the Registrant on the terms of the indemnity contained in the Registrant's Articles.

Under Article 20.3 of the Registrant's Articles, and subject to any restrictions in the BCBCA, the Registrant may indemnify any person. The Registrant has entered into indemnity agreements or employment agreements containing indemnification provisions with certain of the Registrant's directors and officers. Under these indemnification provisions, an executive officer is entitled, subject to the terms and conditions thereof, to the right of indemnification by the Registrant for certain expenses to the fullest extent permitted by applicable law. The Registrant believes that these indemnification agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

Pursuant to Article 20.4 of the Registrant's Articles, the failure of an eligible party to comply with the BCBCA or the Registrant's Articles does not invalidate any indemnity to which he or she is entitled under the Registrant's Articles.

Under Article 20.5 of the Registrant's Articles, the Registrant may purchase and maintain insurance for the benefit of any person (or his or her heirs or legal personal representatives) who: (1) is or was a director, officer, employee or agent of the Registrant; (2) at the request of the Registrant, is or was a director, officer, employee or agent of another corporation at a time when the corporation is or was an affiliate of the Registrant; (3) at the request of the Registrant, is or was a director, officer, employee or agent of a corporation or a partnership, trust, joint venture or other unincorporated entity; (d) at the request of the Registrant, holds or held a position equivalent to that of a director or officer of a partnership, trust, joint venture or other unincorporated entity; against any liability incurred by him or her as such director, officer, employee or agent or person who holds or held such equivalent position.

The Registrant has an insurance policy covering its directors and officers, within the limits and subject to the limitations of the policy, with respect to certain liabilities arising out of claims based on acts or omissions in their capacities as directors or officers.

------

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Item 7. <u>Exemptions from Registration Claimed</u>.

Not applicable

Item 8. <u>Exhibits</u>.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp; **Exhibit<br>Number** | &nbsp;&nbsp; **Exhibit Description** | &nbsp;&nbsp; **Incorporated<br>by<br>Reference<br>Form** | &nbsp;&nbsp; **File No.** | &nbsp;&nbsp; **Exhibit** | &nbsp;&nbsp; **Filing Date** | &nbsp;&nbsp; **Filed<br>Herewith** |
| &nbsp;&nbsp; [4.1](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-1.htm) | &nbsp;&nbsp; [Articles of LexaGene Holdings Inc.](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-1.htm) | &nbsp;&nbsp; [10-12G](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-1.htm) | &nbsp;&nbsp; [000-56456](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-1.htm) | &nbsp;&nbsp; [3.1](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-1.htm) | &nbsp;&nbsp; [2022-06-28](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-1.htm) |  |
| &nbsp;&nbsp; [4.2](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-2.htm) | &nbsp;&nbsp; [Notice of Articles of LexaGene Holdings Inc.](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-2.htm) | &nbsp;&nbsp; [10-12G](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-2.htm) | &nbsp;&nbsp; [000-56456](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-2.htm) | &nbsp;&nbsp; [3.2](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-2.htm) | &nbsp;&nbsp; [2022-06-28](http://www.sec.gov/Archives/edgar/data/1450416/000110465922075186/tm2210382d1_ex3-2.htm) |  |
| &nbsp;&nbsp; [5.1](exhibit5-1.htm) | &nbsp;&nbsp; [Opinion of McMillan LLP](exhibit5-1.htm) |  |  |  |  | &nbsp;&nbsp; [X](exhibit5-1.htm) |
| &nbsp;&nbsp; [23.1](exhibit23-1.htm) | &nbsp;&nbsp; [Consent of RSM USA LLP](exhibit23-1.htm) |  |  |  |  | &nbsp;&nbsp; [X](exhibit23-1.htm) |
| &nbsp;&nbsp; [23.2](exhibit5-1.htm) | &nbsp;&nbsp; [Consent of McMillan LLP (contained in Exhibit 5.1 hereto)](exhibit5-1.htm) |  |  |  |  | &nbsp;&nbsp; [X](exhibit5-1.htm) |
| &nbsp;&nbsp; [24.1](#page_12) | &nbsp;&nbsp; [Powers of Attorney (included on the signature page of this registration statement)](#page_12) |  |  |  |  | &nbsp;&nbsp; [X](#page_12) |
| &nbsp;&nbsp; [99.1](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [Lexagene Holdings Inc. Omnibus Incentive Plan](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [DEF 14A](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [000-56456](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [Schedule A](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [2022-12-30](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) |  |
| &nbsp;&nbsp; [99.2](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [Form of Restricted Share Unit Agreement](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [DEF 14A](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [000-56456](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [Annexed to Schedule A](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [2022-12-30](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) |  |
| &nbsp;&nbsp; [99.3](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [Form of Option Certificate](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [DEF 14A](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [000-56456](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [Annexed to Schedule A](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) | &nbsp;&nbsp; [2022-12-30](http://www.sec.gov/Archives/edgar/data/1450416/000106299322024577/formdef14a.htm) |  |
| &nbsp;&nbsp; [107](exhibitfilingfees.htm) | &nbsp;&nbsp; [Calculation of Filing Fees Table](exhibitfilingfees.htm) |  |  |  |  | &nbsp;&nbsp; [X](exhibitfilingfees.htm) |

---

Item 9. <u>Undertakings</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in the volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

(iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

------

*provided, however,* that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Beverly, Massachusetts, on February 8, 2023.

---

| |
|:---|
| **LEXAGENE HOLDINGS INC.** |
| /s/ Jeffrey Mitchell |
| By: Jeffrey Mitchell |
| Title: Chief Financial Officer |

---

------

**SIGNATURES AND POWERS OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Jeffrey Mitchell and Dr. Jack Regan, or any of them, as his or her true and lawful attorneys-in-fact and agents, each of whom may act alone, with full powers of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments to this registration statement, including post-effective amendments to this registration statement, registration statements filed pursuant to Rule 429 under the Securities Act, and any related registration statements necessary to register additional securities, and to file the same, with all exhibits thereto, and other documents and in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all his or her said attorneys-in-fact and agents or any of them or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

This Power of Attorney may be executed in multiple counterparts, each of which shall be deemed an original, but which taken together shall constitute one instrument.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities indicated on February 8, 2023.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Signature** | &nbsp;&nbsp; **Title** |
| &nbsp;&nbsp; /s/ Dr. Jack Regan | &nbsp;&nbsp; Chief Executive Officer, Chairman & Director |
| &nbsp;&nbsp; Dr. Jack Regan |  |
| &nbsp;&nbsp; /s/ Jeffrey Mitchell | &nbsp;&nbsp; Chief Financial Officer |
| &nbsp;&nbsp; Jeffrey Mitchell |  |
| &nbsp;&nbsp; /s/ Thomas Slezak | &nbsp;&nbsp; Director |
| &nbsp;&nbsp; Thomas Slezak |  |
| &nbsp;&nbsp; /s/ Joseph Caruso | &nbsp;&nbsp; Director |
| &nbsp;&nbsp; Joseph Caruso |  |
| &nbsp;&nbsp; /s/ Stephen Mastrocola | &nbsp;&nbsp; Director |
| &nbsp;&nbsp; Stephen Mastrocola |  |
| &nbsp;&nbsp; /s/ Dr. Jane Sykes | &nbsp;&nbsp; Director |
| &nbsp;&nbsp; Dr. Jane Sykes |  |

---

------

**AUTHORIZED REPRESENTITIVE** 

Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, as amended, the undersigned has signed this Form S-8, solely in its capacity as duly authorized representative of LexaGene Holdings, Inc. in the United States, on February 8, 2023.

---

| |
|:---|
| **LEXAGENE, INC.** |
| /s/ Jeffrey Mitchell |
| By: Jeffrey Mitchell |
| Title: Chief Financial Officer |

---

------

## Exhibit 5.1

------

![](exhibit5-1xu001.jpg)<br>

Our File No.: 235991 <br> Date: February 8, 2023

Lexagene Holdings Inc.<br>500 Cummings Center, Suite 4550<br>Beverly, Massachusetts 01915

Dear Sirs/Mesdames:

**Re: Lexagene Holdings Inc. (the "Company") -**<br>**Omnibus Incentive Plan of the Company, as amended (the "Omnibus Plan")**

We have acted as legal counsel for the Company in connection with the preparation of a registration statement on Form S-8 (the "**Registration Statement**") to be filed by the Company with the Securities and Exchange Commission pursuant to the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**").

The Registration Statement relates to the registration of 8,421,344 common shares of the Company (the "**Plan Shares**") issuable by the Company pursuant to the exercise of stock options ("**Stock Options**") and the payout of restricted stock units ("**RSUs**") granted pursuant to the Company's Omnibus Incentive Plan, as amended (the "**Omnibus Plan**").

**Documents Reviewed**

In rendering the opinion set forth below, we have reviewed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registration Statement and the exhibits thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Notice of Articles of the Company (the "**Notice of Articles**") and Articles of the Company (the "**Articles**") as in effect on the date hereof, and as referred to in the list of Exhibits to the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) certain records of the Company's corporate proceedings as reflected in its minute book, including resolutions of the board of directors approving the Omnibus Plan and the Stock Options and RSUs granted pursuant to the Omnibus Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the Omnibus Plan; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) such other documents as we have deemed relevant.

McMillan LLP \| Royal Centre, 1055 W. Georgia St., Suite 1500, Vancouver, BC, Canada V6E 4N7 \| t 604.689.9111 \| f 604.685.7084<br>Lawyers \| Patent & Trademark Agents \| Avocats \| Agents de brevets et de marques de commerce<br>Vancouver \| Calgary \| Toronto \| Ottawa \| Montréal \| Hong Kong \| mcmillan.ca

------

---

| | |
|:---|:---|
| ![](exhibit5-1xu001.jpg) | February 8, 2023<br>Page 2 |

---

**Assumptions, Limitations and Qualifications**

Our opinion expressed herein is subject in all respects to the following assumptions, limitations and qualifications:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the foregoing opinion is limited to the laws of the Province of British Columbia and the federal laws of Canada applicable therein, including all applicable provisions of the *Business Corporations Act* (British Columbia), as amended (the "**BC Business Corporations Act**"). We have not considered, and have not expressed any opinion with regard to, or as to the effect of, any other law, rule or regulation, state or federal, applicable to the Company. In particular, we express no opinion as to United States federal securities laws, including the U.S. Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) we have assumed (i) the genuineness of all signatures on documents examined by us, (ii) the legal capacity of the officers of the Company, (iii) the authenticity of all documents submitted to us as originals, (iv) the conformity to authentic originals of all documents submitted to us as certified, conformed, photostatic or other copies, and (v) that the documents, in the forms submitted to us for our review, have not been and will not be altered or amended in any respect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) we have assumed that: (i) each Stock Option or RSU granted or to be granted pursuant to the Omnibus Plan has been or will be duly authorized by the board of directors of the Company in accordance with the Articles and Notice of Articles of the Company, the BC Business Corporations Act and the Omnibus Plan; (ii) each agreement governing a Stock Option or RSU under the Omnibus Plan has been or will be duly executed by each party thereto and constitutes or will constitute the legal, valid and binding obligations of the parties thereto, and that such agreements are or will be enforceable against each of the parties thereto in accordance with their respective terms; (iii) any common shares issuable upon exercise of a Stock Option will be issued following payment in full of the exercise price of such Stock Option and in accordance with the Omnibus Plan; and (iv) any common shares issuable upon payout of a RSU will be issued in accordance with the terms of the grant of the RSU and the Omnibus Plan, and any performance requirements and vesting conditions to the payout of such RSU will have been satisfied;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) we have assumed that at the time the Company is or becomes obligated to issue any Plan Shares upon exercise of Stock Options or payout of RSUs granted pursuant to the Omnibus Plan, the Company (i) will have adequate authorized and unissued common shares to fulfill such obligations, and (ii) will be in good standing with the British Columbia Registrar of Companies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) we have assumed that at the time the Company is or becomes obligated to issue any Plan Shares upon exercise of Stock Options or payout of RSUs granted pursuant to the Omnibus Plan, the Articles and Notice of Articles will remain in force, without amendment, and no authorization of the board of directors of the Company with respect to the Omnibus Plan or any Stock Options or RSUs granted under the Omnibus Plan will have been revoked; and

------

---

| | |
|:---|:---|
| ![](exhibit5-1xu001.jpg) | February 8, 2023<br>Page 3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) we have assumed the absence of fraud in any transaction pursuant to which Plan Shares may be issued pursuant to any Stock Option or RSU granted under the Omnibus Plan, and that the consideration authorized by the board of directors for the Plan Shares will have been received by the Company prior to their issuance.

**Opinion**

Subject to the foregoing and the assumptions, limitations and qualifications set forth in this letter, it is our opinion that the Plan Shares will be validly issued and fully paid and non-assessable common shares in the capital of the Company when issued and sold pursuant to the exercise of Stock Options or the payout of RSUs granted pursuant to the Omnibus Plan, provided that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) such Stock Options and RSUs have been granted in accordance with the terms and conditions of the Omnibus Plan; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the persons receiving any Shares upon the exercise of Stock Options or the payout of RSUs granted under the Omnibus Plan have performed their obligations to the Company in accordance with the terms and conditions of the Omnibus Plan and any agreement evidencing the grant of the Stock Options, including the payment of the required exercise price with respect to Stock Options, or RSUs, including the performance of the required services and the satisfaction of all vesting conditions with respect to such RSUs.

The opinion expressed in this letter is rendered as of the date hereof and is based on our understandings and assumptions as to present facts and on the application of the laws of the Province of British Columbia and the federal laws of Canada applicable therein as the same exists on the date hereof. We assume no obligation to update or supplement this opinion letter after the date hereof with respect to any facts or circumstances that may hereafter come to our attention or to reflect any changes in the facts or law that may hereafter occur or take effect.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to the use of our name wherever appearing in the Registration Statement, and in any amendment thereto.

Yours truly,

/s/ McMillan LLP

------

## Exhibit 23.1

------

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of LexaGene Holdings, Inc. of our report dated June 28, 2022, relating to the consolidated financial statements of LexaGene Holdings, Inc. and its subsidiaries, appearing in the Registration Statement on Form 10 of LexaGene Holdings, Inc. for the year ended February 28, 2022.

/s/ RSM US LLP

Boston, Massachusetts

February 8, 2023

------

## Ex-Filing

------

**Calculation of Filing Fee Tables** 

**Form S-8** 

**LEXAGENE HOLDINGS INC.**

**Table 1: Newly Registered Securities** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp; **Security<br>Type** | &nbsp;&nbsp; **Security<br>Class<br>Title** | &nbsp;&nbsp; **Fee<br>Calculation<br>Rule** | &nbsp;&nbsp; **Maximum<br>Aggregate<br>Offering Price** | &nbsp;&nbsp; **Fee Rate** | &nbsp;&nbsp; **Amount of<br>Registration<br>Fee** |
| &nbsp;&nbsp; Equity | &nbsp;&nbsp; Common Shares, no par value | &nbsp;&nbsp; 457(h)<br>&nbsp;&nbsp; 3471950<sup>(2)</sup><br>&nbsp;&nbsp; $0.39<sup>(</sup><sup>5</sup><sup>)</sup> | &nbsp;&nbsp; $1354060 | &nbsp;&nbsp; $110.20 per $1,000,000 | &nbsp;&nbsp; $149.22 |
| &nbsp;&nbsp; Equity | &nbsp;&nbsp; Common Shares, no par value | &nbsp;&nbsp; 457(h)<br>&nbsp;&nbsp; 2057502<sup>(3)</sup><br>&nbsp;&nbsp; $0.26<sup>(</sup><sup>6</sup><sup>)</sup> | &nbsp;&nbsp; $534950 | &nbsp;&nbsp; $110.20 per $1,000,000 | &nbsp;&nbsp; $58.95 |
| &nbsp;&nbsp; Equity | &nbsp;&nbsp; Common Shares, no par value | &nbsp;&nbsp; 457(h) and 457(c)<br>&nbsp;&nbsp; 2891892<sup>(</sup><sup>4</sup><sup>)</sup><br>&nbsp;&nbsp; $0.17<sup>(</sup><sup>7</sup><sup>)</sup> | &nbsp;&nbsp; $491622 | &nbsp;&nbsp; $110.20 per $1,000,000 | &nbsp;&nbsp; $54.18 |
| &nbsp;&nbsp; **Total Offering Amounts** | &nbsp;&nbsp; **Total Offering Amounts** | &nbsp;&nbsp; **Total Offering Amounts** |  |  | &nbsp;&nbsp; $262.35 |
| &nbsp;&nbsp; **Total Fee Offsets** | &nbsp;&nbsp; **Total Fee Offsets** | &nbsp;&nbsp; **Total Fee Offsets** |  |  | &nbsp;&nbsp; $0.00 |
| &nbsp;&nbsp; **Net Fee Due** | &nbsp;&nbsp; **Net Fee Due** | &nbsp;&nbsp; **Net Fee Due** |  |  | &nbsp;&nbsp; $262.35 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "**Securities Act**"), this registration statement covers as indeterminate number of additional Common Shares (as defined below) that may be offered and issued to prevent dilution resulting from share dividends, share splits, reverse share splits, combinations of shares, spin-offs, recapitalizations, mergers or similar capital adjustments as provided in the Omnibus Incentive Plan, as amended (the "**OIP**") of LexaGene Holdings Inc. (the "**Registrant**").

(2) Represents the total number of common shares without par value (the "**Common Shares**") of the Registrant issuable upon the exercise of outstanding stock options granted pursuant to the OIP as of the date of this Registration Statement.

------

(3) Represents the total number of Common Shares issuable upon the payout of outstanding restricted share units granted pursuant to the OIP as of the date of this Registration Statement.

(4) Represents the total number of Common Shares issuable pursuant to additional awards of stock options and restricted share units that may be granted under the OIP.

(5) Estimated solely for the purpose of calculating the registration fee pursuant to 457(h) under the Securities Act and based upon the weighted average exercise price of the outstanding stock options under the OIP.

(6) Estimated solely for the purpose of calculating the registration fee pursuant to 457(h) under the Securities Act and based upon the weighted average grant date value of the outstanding restricted share units under the OIP.

(7) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act and based upon the average of the high and low prices of the Common Shares, as reported on the OTCQB Venture Market on February 7, 2023, which date is within five business days prior to the filing of this Registration Statement, which was $0.17 per share.

------